Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Sustained Effect of Red-light Therapy for Myopia Control: A 2-Year Post-Trial Follow-up Study

A legfontosabb adatok

Ki végzi
Beijing Airdoc Technology Co., Ltd.
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
50 fő vett részt
Kezdés
2020. máj. 13.
Várható befejezés
2026. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • Red-light therapy device
  • Spectacles
A regiszteradat frissítve
2024. február 14.

Ki vehet részt

Életkor
9 év – 13 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 9 feltétel megnézéseKevesebb

Ki vehet részt

  • Clinical diagnosis of myopia
  • Ages of 9~13 years old
  • Must be with best corrected visual acuity ≥20/25 (decimal record)
  • Must be the subject in the previous study of 12-month red-light therapy of myopia

Ki nem vehet részt

  • Clinical diagnosis of glaucoma or retinal lesions
  • Clinical diagnosis of optic media lesions (e.g., central thick corneal scars, cataract)
  • Clinical diagnosis of optic nerve dysfunction
  • Clinical diagnosis of amblyopia
  • Must be eligible for follow-up

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To evaluate the long-term efficacy and safety of red-light therapy for myopia control over 2 years, and the potential rebound effect after treatment cessation.

A teljes eredeti leírásKevesebb

The Chinese myopic children who originally completed the one-year randomised controlled trial in the previous study were enrolled. Children continued or started to daily usage of red-light therapy were defined as the RL group, while those who stopped using red-light therapy and switched to single-vision spectacles (SVS) as well as those who continued to keep single-vision spectacles in the second year were both regarded as the SVS group. Red-light therapy was provided by an at-home desktop light device emitting red-light of 650 nm and was administered for 3 min at a time, twice a day. Changes in axial length (AL) and cycloplegic spherical equivalence refraction (SER) are to be measured and compared as well as the adverse effects including the rebound effect.

Red-light therapy has emerged as a novel myopia control treatment modality recently. A 12-month randomised controlled trial (RCT) conducted by our research team was thought to be earlier to evaluate the treatment of myopic children using red-light therapy. The trial demonstrated that PBM therapy was effective on myopia control, reducing axial elongation and spherical equivalence refraction (SER) progression 103% and 127% compared with single vision spectacle (SVS) over a 12-month period, respectively. The promising efficacy of red-light therapy has been further confirmed in other studies. In addition, satisfactory user acceptability and no unrecovered functional and structural damages were observed.

Myopia generally progresses throughout childhood and hence a study duration of 1 year is not sufficient to widely adopt the red-light therapy as a treatment strategy for myopia control. The sustainability of treatment efficacy, rebound phenomenon upon cessation of treatment, and potential risks and adverse effects in myopic children with longer-term PBM therapy, remain to be fully elucidated.

Thus, the aims of this post-trial follow-up study were to invite the participants to come back for a 24-month visit and to investigate the long-term efficacy and safety of continued red-light therapy as well as the potential rebound effect following red-light treatment cessation.

A vizsgálat 2 csoportja

  • red-light therapy groupA vizsgált kezelés

    The red-light therapy group would be treated with red-light therapy twice daily including the single focus spectacles during the follow-up.

    Kezelés: Red-light therapy device és Spectacles

  • control groupEgyéb csoport

    The control group including both the stopping red-light therapy group from the first 12 months (who obtained red-light therapy but stopped during the second 12-month follow-up) and those never use red-light therapy.

    Kezelés: Spectacles

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Retrospective,2-Year Post-Trial Follow-up Study of Sustained and Rebound Effect of Red-light Therapy for Myopia in Ningbo.
A regiszteradat frissítve
2024. február 14.